James Symanowski

Dr. James Symanowski


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
KKKunal C. Kadakia
Kunal C. Kadakia
JSJames Symanowski
James Symanowski
AAAynur Aktas
Aynur Aktas
MSMichele L. Szafranski
Michele L. Szafranski
JSJonathan C. Salo
Jonathan C. Salo
DWDeclan Walsh
Declan Walsh

15 January 2025 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
TMTori L. McFarlane
Tori L. McFarlane
JSJames Symanowski
James Symanowski
DWDeclan Walsh
Declan Walsh
YAYe Myint Aung
Ye Myint Aung
AAAynur Aktas
Aynur Aktas
KKKunal C. Kadakia
Kunal C. Kadakia
Purpose Malnutrition severely impacts tolerance to anticancer therapies, but any relationship with overall survival (OS) at the time of solid tumour diagnosis in outpatients in the USA remains unclear. Methods This retrospective study evaluated 3562 patients who completed the Malnutrition Screening Tool (MST) at diagnosis, identifying the relationship between MST risk, a validated tool evaluating anorexia and weight loss, and OS. MST score of ≥2 of 5 was classified as high malnutrition risk (H-MST). Kaplan-Meier techniques and Cox proportional hazards models were used to analyse OS in H-MST versus low malnutrition risk (L-MST). Results In the unadjusted models, MST risk was individually associated with OS. Multivariable regression confirmed that MST risk remained independently prognostic for OS after controlling for key confounding variables, HR=1.51 (95% CI: 1.33 to 1.72). The H-MST group had shorter OS (50-month survival rates: 69% L-MST vs 60% H-MST). Conclusion MST risk at diagnosis is an independent prognostic factor for OS. H-MST risk is associated with shorter survival in a broad cohort of solid tumour oncology outpatients.

24 May 2024 in Annals of Surgery
Verified
Journal Article
Open access
LHLejla Hadzikadic-Gusic
Lejla Hadzikadic-Gusic
JBJessica Bilz
Jessica Bilz
DBDanielle Boselli
Danielle Boselli
JSJames Symanowski
James Symanowski
MWMichelle Wallander
Michelle Wallander
RWRichard L White
Richard L White
Objective: Compare radioactive seed localization (RSL) and wire-guided localization (WL) for nonpalpable malignant breast disease. Background: While WL has been the most common approach for localization of nonpalpable breast tumors, other techniques such as RSL, intraoperative ultrasound, radioactive intraoperative occult lesion localization, hematoma localization, radar localization, and magnetic seed localization have been suggested as safe and efficacious alternatives. However, very few randomized controlled trials have compared these localization techniques. Methods: Between July 2015 and January 2021, 400 women with nonpalpable malignant breast disease were randomized 1:1 to RSL or WL, stratified by the surgeon and invasive disease status. The primary outcome was initial resection negative margin rates. Secondary outcomes included time efficiencies, cost, and satisfaction. Results: There was no significant difference in negative margin rates between RSL and WL [RSL 0.80 (95% CI: 0.75–0.86) vs WL 0.85 (95% CI: 0.80–0.89); P =0.29]. RSL received better patient scores for anxiety [OR=2.62 (95% CI: 1.79–3.84); P <0.01], pain [OR=2.50 (95% CI: 1.69–3.71); P <0.01], and overall satisfaction [OR=3.24 (95% CI: 1.70–6.22); P <0.01] compared with WL. Radiologists and surgeons associated RSL with better convenience [OR=3.32 (95% CI: 1.65–6.69); P <0.01] and satisfaction of surgical procedure conduct [OR=1.67 (95% CI: 1.09–2.58); P =0.02]. Time in radiology did not differ [RSL mean (SD) 12.8±9.5 min vs. WL 11.4±6.0 min; P =0.18]. RSL incurred a $600 higher cost than WL. Conclusions: The results of the largest randomized controlled trial in the United States support RSL as an acceptable alternative to WL in the treatment of nonpalpable malignant breast disease. While RSL was not superior to WL in achievement of negative margins, patients and providers reported improved satisfaction scores.